Sayyah Mehdi, Boostani Hatam, Ashrafpoori Mitra, Pakseresht Siroos
Faculty member of Education Development Center (EDC), Psychiatrist, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Faculty member of Psychiatry Group, Psychiatrist, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Iran J Pharm Res. 2015 Fall;14(4):1269-74.
The aim of this study was to evaluate the effects of Atorvastatin on negative symptoms in patients with chronic schizophrenia. The study was a prospective, double-blind, 6-week trial. Forty patients participated in the study; 19 patients were assigned to the Atorvastatin group as well as 21 patients to the placebo group. For assessing negative signs, we used Scale for the Assessment of Negative Symptoms (SANS) in weeks 1st, 3nd, 4th, and 6th. Moreover, patients were randomly assigned to treatment groups with Risperidone (6 mg/day) plus 20 mg Atorvastatin or with Risperidone (6 mg/day) plus placebo. Mean scores of Scale for the Assessment of Negative Symptoms (SANS) decreased during the treatment but there was no significant difference between the mean scores of two groups. The result of this trial suggested that Atorvastatin can be effective in reducing negative sign in schizophrenia although further studies seem to be needed.
本研究的目的是评估阿托伐他汀对慢性精神分裂症患者阴性症状的影响。该研究是一项前瞻性、双盲、为期6周的试验。40名患者参与了研究；19名患者被分配到阿托伐他汀组，21名患者被分配到安慰剂组。在第1周、第3周、第4周和第6周，我们使用阴性症状评定量表（SANS）来评估阴性症状。此外，患者被随机分配到接受利培酮（6毫克/天）加20毫克阿托伐他汀治疗的组或接受利培酮（6毫克/天）加安慰剂治疗的组。阴性症状评定量表（SANS）的平均得分在治疗期间有所下降，但两组的平均得分之间没有显著差异。该试验结果表明，阿托伐他汀可能对减轻精神分裂症的阴性症状有效，尽管似乎还需要进一步研究。
